摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(S)-1-(allyloxy)-3-methylbutan-2-amine | 500708-37-2

中文名称
——
中文别名
——
英文名称
(S)-1-(allyloxy)-3-methylbutan-2-amine
英文别名
O-allyl-L-valinol;(S)-1-allyloxymethyl-2-methylpropylamine;(2S)-3-methyl-1-prop-2-enoxybutan-2-amine
(S)-1-(allyloxy)-3-methylbutan-2-amine化学式
CAS
500708-37-2
化学式
C8H17NO
mdl
——
分子量
143.229
InChiKey
OCPXVDYUUXFZPT-MRVPVSSYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.2
  • 重原子数:
    10
  • 可旋转键数:
    5
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.75
  • 拓扑面积:
    35.2
  • 氢给体数:
    1
  • 氢受体数:
    2

反应信息

点击查看最新优质反应信息

文献信息

  • Tetrahydroquinoline-Derived Macrocyclic Toolbox: The Discovery of Antiangiogenesis Agents in Zebrafish Assay
    作者:Shiva Krishna Reddy Guduru、Srinivas Chamakuri、Gayathri Chandrasekar、Satish Srinivas Kitambi、Prabhat Arya
    DOI:10.1021/ml400026n
    日期:2013.7.11
    incorporate the macrocyclic rings onto the privileged substructure, i.e., tetrahydroquinoline scaffold, is developed. The presence of an amino acid-derived moiety in the macrocyclic skeleton provides an opportunity to modulate the nature of the chiral side chain. Further, evaluation in a zebrafish screen identified three active small molecules (2.5b, 3.2d, and 4.2) as antiangiogenesis agents at 2.5 muM
    开发了一种将大环结合到特权子结构(即四氢喹啉骨架)上的新颖方法。大环骨架中氨基酸衍生部分的存在为调节手性侧链的性质提供了机会。此外,在斑马鱼筛选中的评估确定了三个活性小分子(2.5b,3.2d和4.2)为2.5μM的抗血管生成剂。
  • Practical Stereoselective Synthesis of Eribulin Fragment toward Building a Hybrid Macrocyclic Toolbox
    作者:Ravikumar Jimmidi、Shiva Krishna Reddy Guduru、Prabhat Arya
    DOI:10.1021/ol503464s
    日期:2015.2.6
    A practical stereoselective synthesis to obtain the substituted furan ring as the substructure of eribulin is developed. An asymmetric syn-aldol and intramolecular oxy-Michael were two key steps in our approach. The functionalized furan derivatives were then utilized further to build the 14- and 12-membered macrocyclic diversity as trans- and cis-fused (C-29 and C-30) compounds. This is the first report
    开发了一种实用的立体选择性合成方法,以获得取代的呋喃环作为eribulin的亚结构。不对称的顺式羟醛和分子内的氧-迈克尔是我们方法中的两个关键步骤。然后将官能化的呋喃生物进一步利用构建14-和12-元大环多样性反式-和顺-融合(C-29和C-30)的化合物。这是首次建立具有大环小分子的化学工具箱的化学工具箱,该大环小分子具有包含eribulin及其非对映异构体亚结构的反式或顺式稠合的14或12元环。
  • MACROCYCLIC UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIA
    申请人:Kallus Christopher
    公开号:US20140039011A1
    公开(公告)日:2014-02-06
    The invention relates to compounds of the formula (I) which are inhibitors of activated thrombin-activable fibrinolysis inhibitor. The compounds of the formula I are suitable for producing medicaments for prophylaxis, secondary prevention and treatment of one or more disorders associated with thromboses, embolisms, hypercoagulability or fibrotic changes.
    本发明涉及公式(I)的化合物,它们是活化的凝血酶-可激活纤溶抑制剂抑制剂。公式I的化合物适用于生产预防、次级预防和治疗与血栓、栓塞、高凝状态或纤维化变化相关的一个或多个疾病的药物。
  • Macrocyclic urea and sulfamide derivatives as inhibitors of TAFIa
    申请人:Kallus Christopher
    公开号:US08580777B2
    公开(公告)日:2013-11-12
    The invention relates to compounds of the formula (I) which are inhibitors of activated thrombin-activable fibrinolysis inhibitor. The compounds of the formula I are suitable for producing medicaments for prophylaxis, secondary prevention and treatment of one or more disorders associated with thromboses, embolisms, hypercoagulability or fibrotic changes.
    本发明涉及式(I)的化合物,它们是激活的凝血酶激活纤溶抑制剂抑制剂。式(I)的化合物适用于制备用于预防、次级预防和治疗与血栓、栓塞、高凝状态或纤维化变化有关的一个或多个疾病的药物。
  • Macrocyclic urea and sulfamide derivatives as inhibitors of tafia
    申请人:Kallus Christopher
    公开号:US08722655B2
    公开(公告)日:2014-05-13
    The invention relates to compounds of the formula (I) which are inhibitors of activated thrombin-activable fibrinolysis inhibitor. The compounds of the formula I are suitable for producing medicaments for prophylaxis, secondary prevention and treatment of one or more disorders associated with thromboses, embolisms, hypercoagulability or fibrotic changes.
    本发明涉及式(I)的化合物,它们是激活的凝血酶激活纤溶抑制剂抑制剂。式(I)的化合物适用于制备用于预防、次级预防和治疗与血栓、栓塞、高凝状态或纤维化变化有关的一种或多种疾病的药物。
查看更多